Featuring perspectives from Dr Gloria Gerber, Dr Jamie Koprivnikar, Prof Alexander Röth and Dr Jamile M Shammo, including the following topics:

Introduction: Paroxysmal Nocturnal Hemoglobinuria (PNH) and the General Medical Oncologist

Overview — Biology and Pathophysiology

Role of complement activation in PNH; classification and clinical presentation (7:00)
PNH treatments and their complement targets (21:37)

Current Management Approaches

Mechanistic similarities and differences between crovalimab and other available C5 inhibitors; potential practical advantages of crovalimab (24:56)
Timing for initiation of treatment for PNH (32:08)
Management of clinically significant extravascular hemolysis and residual anemia in patients with PNH receiving C5 inhibitor therapy (43:08)
Risk of evolution to aplastic anemia or myeloid malignancy (45:54)
Clinical trial database establishing the efficacy and safety of the C5 complement inhibitors eculizumab and ravulizumab for PNH (48:47)
Activity and safety of and clinical experience with crovalimab (53:03)
Monitoring and management of PNH in pregnant patients (58:37)

Case Presentations

Case: A woman in her early 30s who receives a new diagnosis of classical PNH with symptomatic anemia — Dr Gerber (1:03:44)
Case: A man in his early 30s with PNH initially treated with eculizumab who is transitioned to ravulizumab — Dr Koprivnikar (1:17:32)
Case: A woman in her early 50s with a remote history of aplastic anemia — Dr Gerber (1:32:24)
Case: A woman in her late 20s with PNH receiving active C5 inhibitor therapy who wishes to discuss alternative treatment options — Dr Koprivnikar (1:38:00)

“Camões, poeta zarolho, fez versos à D. Inês” e agora dá nome a mais um aeroporto